Eli Lilly raises full-year revenue guidance by $3B: We unpack the drugmaker’s Q2 financials and explore how rebounding drug availability has GLP-1 momentum swinging Eli Lilly’s way.
Abbott, Medtronic partner to pair connected devices with insulin delivery systems: At first glance, the tie-up between diabetes competitors seems odd—but the opportunities the collaboration provides will ultimately benefit both parties.
CVS, Humana disappoint investors with slumping Medicare Advantage segments: Big bets on the MA market aren’t paying off as some insurers anticipated.
UNC Health launches PBM: Newer PBM models are being rolled out by a slew of industry players in response to the lack of drug price transparency.
Health apps will get easier access to patients’ medical data: Epic’s new EHR capability is making it possible. We explore what it will take for consumers to trust digital health apps with their medical information.
US consumers show optimism over AI adoption in healthcare: Americans are becoming more open to the use of the tech in their care—so long as the tech doesn't replace human interactions.
Hims & Hers plows ahead with compounded weight loss drugs: Hims is betting that neither the FDA nor GLP-1 drugmakers will come after the company for continuing to produce compounded versions once shortages end.
Docs’ issues with Medicare and Medicaid in 2024: Reimbursement rates top the list. We examine what the ongoing tension between physicians and insurers means for patients.
Children in the US feel mixed emotions daily: Social media is a likely enabler. We explore how healthcare providers and marketers can step up to educate youths and their parents.
Another employer gets sued for driving up workers’ Rx costs: But it’s the pharmacy benefit managers that really should be held accountable. Here’s why.
Gen Zers’ and millennials’ patient experience leaves a lot to be desired: Not adapting to younger patients’ expectations could spell trouble for healthcare providers.
Teladoc’s mental health business fails to deliver in Q2: We explore what went wrong with BetterHelp and examine how Teladoc plans to right the ship.
Flo Health raises $200M: The period- and pregnancy-tracking app was at a crossroads just a few years ago. We explore how it came out on the other side stronger than ever.
The most important pharmacy trends of 2024: We explore where consumers fill their prescriptions and examine how online players can gain market share.
Google terminates enterprise contract with One Medical: It’s another setback for One Medical since Amazon took ownership. We explore how it could affect Amazon’s go-forward strategy for its primary care business.
Northwell enters uncharted healthcare marketing territory with a studio division: Launching an entertainment business is a risky bet for a health system. Here’s why.
Healthcare organizations are moving slow with genAI tools: They’re concerned with the tech’s risks and unclear industry regulations. Here’s what it means for AI developers.
Walmart is expanding its specialty pharmacy presence: With a multi-billion dollar market opportunity in-play, its decision to open 25 new autoimmune-focused specialty pharmacies across the US is smart business.
CVS Caremark to pay $45M to Illinois in PBM settlement: While it may seem like the walls are finally closing in on PBMs, paying multi-million dollar settlements is just part of doing business for pharma’s middlemen.
New GLP-1 users are more likely to have obesity than diabetes: The trend is concerning for some patients, but not for Big Pharma.